Price T Rowe Associates Inc Aurinia Pharmaceuticals Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 45,707 shares of AUPH stock, worth $343,716. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,707
Previous 38,952
17.34%
Holding current value
$343,716
Previous $196,000
33.16%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding AUPH
# of Institutions
190Shares Held
56.4MCall Options Held
499KPut Options Held
637K-
Armistice Capital, LLC New York, NY11.1MShares$83.7 Million0.83% of portfolio
-
Black Rock Inc. New York, NY9.27MShares$69.7 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$29.9 Million2.14% of portfolio
-
State Street Corp Boston, MA2.88MShares$21.7 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.78MShares$20.9 Million1.94% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.07B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...